Policy development · Digital health & life sciences
Privacy & Security Policy Development for Biotech & Pharma Companies
Policy development for a biotech or pharma company has to produce documents that satisfy two audiences reading them for different reasons: a GCP or GMP inspector checking data integrity, and a security or privacy reviewer checking access control and consent. The trigger is usually a new PSP about to launch, a licensing partner's diligence request for written policy, or an inspection finding that access-control documentation didn't exist in the form expected. We write the policies once, in language both audiences accept, instead of maintaining two versions that eventually contradict each other.
Reviewed by the Privacy Horizon team · Last reviewed
What you're protecting
What policy documents have to cover in this sector
Each policy in this environment has to do double duty, holding up under an inspector's data-integrity review and a partner's security questionnaire at the same time.
Data integrity and access-control policy
A single document describing who can access, change and approve trial, safety and manufacturing records, written to satisfy both a GCP/GMP inspector's expectations and a CISO's access-governance review.
PSP consent and notice language
Enrolment consent forms that plainly describe what the hub vendor does with a patient's data and where that data may cross borders, not boilerplate copied from a template built for a different program.
Scientific IP handling and confidentiality policy
Written rules for how unfiled research is classified, who may access it, and what happens when it is shared with a CRO, a partner or an external collaborator.
Vendor and CRO oversight policy
Documented expectations for how the company reviews and manages CROs, hub vendors and specialty pharmacies, so oversight doesn't depend on one person's memory of what was agreed.
Role-specific acceptable-use guidance
Separate, plain-language guidance for bench scientists handling IP-grade data and patient-services staff handling diagnoses, rather than one generic policy that fits neither group well.
Regulatory map
The regulatory expectations these policies are written against
Two different rulebooks converge on the same documents in this sector, and policy that only satisfies one of them creates a gap the other will eventually find.
Good clinical practice and data-integrity expectations
Sponsors must conduct trials under good clinical practices, and Health Canada's inspection programs expect documented, followed access-control and data-handling procedures behind that requirement.
The fifteen-year record-retention requirement
Trial records must remain complete, accurate and verifiable for fifteen years, which shapes what a records-retention and archival policy has to specify well beyond a typical corporate schedule.
PIPEDA's meaningful-consent standard
Consent for a patient support program has to be genuinely informed, which means the form itself has to name the categories of vendor involved and what happens to the data, not bury it in generic legal language.
Quebec's cross-border transfer expectations
Programs reaching Quebec residents face their own documented assessment expectations for personal information moving outside the province, which consent and vendor policies need to reflect explicitly.
What goes wrong
What weak policy documents expose in this sector
The failures policy work is meant to prevent here rarely look dramatic on their own — they surface as a finding, a complaint, or a diligence question nobody can answer cleanly.
A consent form that doesn't survive scrutiny
Vague PSP consent language that never mentions the hub vendor by category, or says nothing about cross-border data flows, is one of the fastest ways to draw a privacy complaint once a patient asks where their information actually went.
An inspection finding on undocumented access control
A GCP or GMP inspector who cannot find a written policy behind an access-control practice treats the practice as unproven, regardless of how well it may actually be followed day to day.
Vendors filling gaps a policy left open
When the company's own policy is silent on cross-border flows or sub-processor use, the vendor's own contract terms end up setting the standard by default, often without anyone at the company deciding that was acceptable.
IP shared without a documented handling standard
Unfiled research passed to a partner or CRO without a written confidentiality and access policy behind it leaves the company with no documented standard to point to if that data later surfaces somewhere it shouldn't.
Our policy development for biotech & pharma companies
What our policy development covers for a biotech or pharma company
The same core policy work our service always delivers, written specifically for trial data integrity, PSP consent and unfiled science.
Custom policies reflecting how the company actually runs
Data-integrity, consent and IP-handling policies built around your actual trial systems, PSP structure and vendor relationships, not a generic template with the company name changed.
Compliance-ready drafting across two frameworks at once
Language aligned to PIPEDA, Quebec Law 25 and Division 5 data-integrity expectations simultaneously, so one document satisfies both an inspector and a privacy reviewer.
Employee and vendor guidelines by role
Distinct, usable guidance for bench science, patient-services and vendor-facing staff, plus documented expectations for CROs, hubs and specialty pharmacies.
Ongoing updates as the program evolves
Revisions as new trials start, new PSPs launch, or new vendors come on board, so policy documents describe the environment you actually operate today.
How the engagement runs
How policy development runs for a biotech or pharma company
Grounded in your existing trial and PSP workflows before a single word is drafted.
Step 1
Review current documentation and gaps
We assess existing policies, consent forms and vendor agreements against both GCP/GMP expectations and privacy law, and identify what's missing or contradictory.
Step 2
Draft against real workflows
Policies are written to describe how trial data, PSP enrolment and IP handling actually work in your organization, not an idealized version of it.
Step 3
Align both audiences
Language is checked against both inspection expectations and privacy-law standards before anything is finalized, closing the gap between the two.
Step 4
Roll out and maintain
Policies are introduced to the relevant teams and kept current as trials, PSPs and vendor relationships change over time.
What it costs
What determines policy development cost for a biotech or pharma company
Cost depends on how many distinct policy documents are needed — data integrity, PSP consent, IP handling and vendor oversight each require separate drafting — and how many active trials, PSPs and cross-border data flows the policies have to account for.
A pre-clinical company drafting its first IP-handling and vendor policy costs less than a company launching a new PSP that needs consent language covering a hub vendor and cross-border transfers at the same time. We scope pricing after reviewing what already exists and what the current program requires.
Biotech & Pharma Companies: Policy development questions, answered
A single access-control and data-integrity policy that specifies who may create, change and approve records, how changes are logged, and how that logging is reviewed will generally satisfy both audiences, provided it describes what is actually practiced rather than an aspirational process. Written separately, the two versions tend to drift apart and undermine each other.
They should name the categories of vendor involved, such as a hub or specialty pharmacy, describe in plain terms what those vendors do with the patient's information, and disclose whether that data may be processed or stored outside the province or the country. Generic consent language that omits these specifics is unlikely to meet PIPEDA's meaningful-consent standard.
Yes. Bench scientists handling unpublished research face very different risks than patient-services staff handling diagnoses and enrolment forms, and a single generic acceptable-use policy tends to feel irrelevant to both. Role-specific guidance gets read and followed far more consistently than a one-size-fits-all document.
At minimum whenever a new trial starts, a new PSP launches, or a vendor relationship changes materially, plus a periodic review even without a trigger event. A policy describing a vendor relationship that ended two years ago undermines credibility with both an inspector and a diligence reviewer.
Existing PIPEDA-aligned policies are usually a genuine head start rather than a wasted effort. The work is adding the data-integrity and GCP/GMP-specific expectations, and the PSP- and IP-specific detail, that a general privacy policy template was never written to include.
More for biotech & pharma companies
Other services for this niche
About this service
What's Protecting Your Business from the Next Threat?
Don't wait for a breach to expose your vulnerabilities. Let Privacy Horizon secure your data, ensure compliance, and build lasting trust.